Paris, France – 11 January 2021 – Seventure Partners, one of Europe’s leaders in financing innovation and a world leader in life science microbiome investment, has increased focus on skin microbiome investments in its Health for Life fund portfolio, with four companies active in this area, including BiomX, Dermala, Siolta Therapeutics and Eligo Bioscience.
The first Health for Life fund was launched in 2014, as the first fund with a specific focus on microbiome-related investments, with a portfolio that today comprises >20 companies. With microbiome research becoming increasingly important, Seventure has also expanded its investment portfolio to new, emerging areas, such as the skin microbiome. Recent examples of its activities and portfolio company news include:
“While microbiome research is a relatively young area, our understanding of the close connection between the human microbiome and our immune system is growing by the day. This is also reflected by the growing number of major deals in this field, in many modalities and in many therapeutic areas, including the skin microbiome, which is increasingly drawing attention from major skincare companies,” said Isabelle de Cremoux, CEO and Managing Partner, Seventure Partners, who led Health for Life Capital fund raising and microbiome strategy.
Seventure’s second Health for Life Fund II was launched in March 2019, and due to significant interest, its final close has been extended until Spring 2021. This second fund is significantly oversubscribed, already exceeding the initial €200m target size. The fund has already made eight investments in the microbiome space.
About Seventure Partners
With €750m net commitments under management as of the end of 2018, Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure Partners has been investing in innovative businesses with high growth potential in two fields: Life sciences across Europe, Israel, Asia and North America and Digital technologies in France and Germany.
In Life sciences, the main areas of focus include “classic” approaches such as biotechnology and pharmaceuticals, diagnostic and medtech, industrial biotechnology, as well as “beyond the pill” approaches such as MICROBIOME-linked innovations, nutrition, foodtech, digital/connected health, wellbeing and personalized medicine& personalized nutrition. Investments can range between €500k and €10m per round, or up to €20m per company, from early to late stage.
Seventure Partners successfully launched Health for Life Capital™ which invests in Life sciences (health, nutrition, digital/connected health…) with a core focus on the microbiome revolution and its applications in human health, nutrition and food.
In March 2018, Seventure Partners launched AVF, a new fund dedicated to animal nutrition, feed and health with Adisseo as strategic partner. In July 2019, it launched Sport & Performance Capital, dedicated to innovations in Sport & wellness.
About Health for Life Capital™
Seventure Partners launched Health for Life Capital™, the first venture capital fund focused mainly on investments “beyond the pill” in the microbiome and nutrition space. Europe is the primary focus of the fund, but it also invests in North America, Asia and Israel.
The €160m first fund launched in 2014 has invested in 20 companies at the forefront of their fields, such as Enterome, Vedanta Biosciences, MaaT Pharma, Eligo Bioscience, LNC Therapeutics/Ysopia Bioscience, TargEDys, A-Mansia Biotech, BiomX, Microbiotica, Anaeropharma, LiMM Therapeutics, Siolta Therapeutics, DayTwo, Zipongo (renamed Foodsmart), Mdoloris Medical Systems, MycoTechnology, etc.
In January 2019 it launched second fund Health for Life Capital II™ with a target fund size of over €200m. Both first fund and second fund attracted strategic investments from prestigious organisations including Danone, Novartis, two US based global food ingredient providers (to be disclosed), Lesaffre, Tornier, Tereos, Unigrains and Bel, as well as financial institutions, family offices and entrepreneurs.
For more information please contact: email@example.com
Melanie Toyne-SewellManaging Partner